Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy

Joseph A. Khawly, Peter Saloupis, Diane L. Hatchell, Robert Machemer

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


A condition similar to proliferative vitreoretinopathy (PVR) in man can be produced by injecting 25000 homologous dermal fibroblasts into rabbit eyes following gas compression of the vitreous. Daunorubicin (15 nmol) was effective in preventing retinal detachment in this model when injected simultaneously with the fibroblasts or in two doses (10 nmol followed by 5 nmol 4 h later) on the 3rd day after fibroblast injection. A single dose of 15 nmol on the 3rd day was not effective in preventing retinal detachment. These results suggest that daunorubicin may be clinically useful in preventing PVR when given by injection both at the time of vitrectomy as well as later, when protein exudation and pigment clumps in the vitreous cavity herald the onset of PVR.

Original languageEnglish (US)
Pages (from-to)464-467
Number of pages4
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Issue number5
StatePublished - Sep 1991

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy'. Together they form a unique fingerprint.

Cite this